Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

ABC News' Dr. Tara Narula breaks down the FDA's decision to stop the making of compound versions of weight loss medications.

PatchMD, a leading innovator in transdermal nutrient delivery, is excited to announce the launch of its new GLP-1 Support ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

NotCo announced Thursday the launch of its GLP Booster, a product that can be mixed into any food to naturally help you feel ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

GLP-1 agonists, also known as incretin mimetics, are a class of medication that is primarily used to treat type 2 diabetes and, in some cases, obesity. "The glucagon-like peptide (GLP-1 ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...